EUSA Pharma

European Commission approves EUSA Pharma’s dinutuximab beta for neuroblastoma

Wednesday, May 10, 2017

EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, has announced that the European Commission has approved Dinutuximab beta for the treatment of patients with high-risk neuroblastoma. Dinutuximab beta is the only anti-GD2 monoclonal antibody approved in the European Union (EU). EUSA Pharma will begin commercializing Dinutuximab beta across the EU immediately.

[Read More]